Logo image of CELC

CELCUITY INC (CELC) Stock Fundamental Analysis

NASDAQ:CELC - Nasdaq - US15102K1007 - Common Stock - Currency: USD

10.9  +0.1 (+0.93%)

After market: 10.9 0 (0%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CELC. CELC was compared to 566 industry peers in the Biotechnology industry. CELC may be in some trouble as it scores bad on both profitability and health. CELC is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CELC had negative earnings in the past year.
CELC had a negative operating cash flow in the past year.
In the past 5 years CELC always reported negative net income.
CELC had a negative operating cash flow in each of the past 5 years.
CELC Yearly Net Income VS EBIT VS OCF VS FCFCELC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

With a Return On Assets value of -45.60%, CELC perfoms like the industry average, outperforming 51.06% of the companies in the same industry.
CELC has a Return On Equity (-96.68%) which is in line with its industry peers.
Industry RankSector Rank
ROA -45.6%
ROE -96.68%
ROIC N/A
ROA(3y)-33.98%
ROA(5y)-41.85%
ROE(3y)-57.49%
ROE(5y)-59.3%
ROIC(3y)N/A
ROIC(5y)N/A
CELC Yearly ROA, ROE, ROICCELC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

CELC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CELC Yearly Profit, Operating, Gross MarginsCELC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

3

2. Health

2.1 Basic Checks

The number of shares outstanding for CELC has been increased compared to 1 year ago.
The number of shares outstanding for CELC has been increased compared to 5 years ago.
The debt/assets ratio for CELC is higher compared to a year ago.
CELC Yearly Shares OutstandingCELC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
CELC Yearly Total Debt VS Total AssetsCELC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -0.14, we must say that CELC is in the distress zone and has some risk of bankruptcy.
CELC's Altman-Z score of -0.14 is fine compared to the rest of the industry. CELC outperforms 63.60% of its industry peers.
A Debt/Equity ratio of 0.85 indicates that CELC is somewhat dependend on debt financing.
The Debt to Equity ratio of CELC (0.85) is worse than 77.39% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.85
Debt/FCF N/A
Altman-Z -0.14
ROIC/WACCN/A
WACCN/A
CELC Yearly LT Debt VS Equity VS FCFCELC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 7.71 indicates that CELC has no problem at all paying its short term obligations.
CELC has a Current ratio of 7.71. This is in the better half of the industry: CELC outperforms 73.32% of its industry peers.
A Quick Ratio of 7.71 indicates that CELC has no problem at all paying its short term obligations.
The Quick ratio of CELC (7.71) is better than 73.50% of its industry peers.
Industry RankSector Rank
Current Ratio 7.71
Quick Ratio 7.71
CELC Yearly Current Assets VS Current LiabilitesCELC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

CELC shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -4.46%.
EPS 1Y (TTM)-4.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-30.77%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

CELC is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.68% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-29.89%
EPS Next 2Y-7.04%
EPS Next 3Y20.68%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CELC Yearly Revenue VS EstimatesCELC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 500M 1B
CELC Yearly EPS VS EstimatesCELC Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -1 -2 -3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CELC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CELC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CELC Price Earnings VS Forward Price EarningsCELC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CELC Per share dataCELC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as CELC's earnings are expected to grow with 20.68% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-7.04%
EPS Next 3Y20.68%

More info and screens

0

5. Dividend

5.1 Amount

CELC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CELCUITY INC

NASDAQ:CELC (5/2/2025, 8:00:00 PM)

After market: 10.9 0 (0%)

10.9

+0.1 (+0.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-31 2025-03-31/amc
Earnings (Next)05-19 2025-05-19/amc
Inst Owners75.35%
Inst Owner Change0.13%
Ins Owners13.02%
Ins Owner Change-2.86%
Market Cap412.46M
Analysts85.71
Price Target29.07 (166.7%)
Short Float %6.58%
Short Ratio6.56
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-11.36%
Min EPS beat(2)-17.61%
Max EPS beat(2)-5.12%
EPS beat(4)2
Avg EPS beat(4)-0.22%
Min EPS beat(4)-17.61%
Max EPS beat(4)11.42%
EPS beat(8)3
Avg EPS beat(8)-2.51%
EPS beat(12)3
Avg EPS beat(12)-10.79%
EPS beat(16)3
Avg EPS beat(16)-20.18%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-8.06%
PT rev (3m)-2.29%
EPS NQ rev (1m)-20.23%
EPS NQ rev (3m)-24.16%
EPS NY rev (1m)-12.13%
EPS NY rev (3m)-16.51%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-100%
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.57
P/tB 3.57
EV/EBITDA N/A
EPS(TTM)-2.81
EYN/A
EPS(NY)-3.65
Fwd EYN/A
FCF(TTM)-2.21
FCFYN/A
OCF(TTM)-2.21
OCFYN/A
SpS0
BVpS3.06
TBVpS3.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -45.6%
ROE -96.68%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.98%
ROA(5y)-41.85%
ROE(3y)-57.49%
ROE(5y)-59.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.85
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 192.23%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.71
Quick Ratio 7.71
Altman-Z -0.14
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)112.26%
Cap/Depr(5y)77.3%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-30.77%
EPS Next Y-29.89%
EPS Next 2Y-7.04%
EPS Next 3Y20.68%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-41.7%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-55.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-55.11%
OCF growth 3YN/A
OCF growth 5YN/A